Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL729957 | 1.00 | AGTR1 (0.30) | AGTR1MEN1NPC1POLBOPRK1 | |
| SCHEMBL729602 | 0.83 | CCR1 (0.42) | — | |
| SCHEMBL729287 | 0.78 | MEN1 (0.41) | MEN1RAB9AKMT2A | |
| SCHEMBL3332836 | 0.75 | MEN1 (0.37) | AGTR1MEN1NPC1POLBOPRK1 | |
| SCHEMBL3332842 | 0.75 | MEN1 (0.37) | AGTR1MEN1NPC1POLBOPRK1 | |
| SCHEMBL1963841 | 0.70 | RAB9A (0.46) | MEN1NPC1POLBRAB9AKMT2A | |
| SCHEMBL1963840 | 0.70 | RAB9A (0.46) | MEN1NPC1POLBRAB9AKMT2A | |
| SCHEMBL13739948 | 0.66 | CCR1 (0.48) | AGTR1MEN1NPC1POLBOPRK1 | |
| SCHEMBL13738235 | 0.66 | CCR1 (0.44) | — | |
| SCHEMBL16600727 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137184-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-05-08 | — | — | EP | disclosed |
| US-8138181-B2 | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100029633-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029633-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | AGTR1 71/4885MEN1 2334/4885NPC1 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.